IL101574A0 - Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia - Google Patents

Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia

Info

Publication number
IL101574A0
IL101574A0 IL101574A IL10157492A IL101574A0 IL 101574 A0 IL101574 A0 IL 101574A0 IL 101574 A IL101574 A IL 101574A IL 10157492 A IL10157492 A IL 10157492A IL 101574 A0 IL101574 A0 IL 101574A0
Authority
IL
Israel
Prior art keywords
treatment
pharmaceutical compositions
benign prostatic
prostatic hyperplasia
combination pharmaceutical
Prior art date
Application number
IL101574A
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL101574A0 publication Critical patent/IL101574A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL101574A 1991-04-17 1992-04-13 Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia IL101574A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68672091A 1991-04-17 1991-04-17
US74638891A 1991-08-16 1991-08-16
US84615592A 1992-03-11 1992-03-11

Publications (1)

Publication Number Publication Date
IL101574A0 true IL101574A0 (en) 1992-12-30

Family

ID=27418473

Family Applications (1)

Application Number Title Priority Date Filing Date
IL101574A IL101574A0 (en) 1991-04-17 1992-04-13 Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia

Country Status (5)

Country Link
AU (1) AU1893492A (en)
IE (1) IE921239A1 (en)
IL (1) IL101574A0 (en)
PT (1) PT100388A (en)
WO (1) WO1992018132A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698720A (en) * 1992-04-20 1997-12-16 Sankyo Company, Limited Steroid derivatives
ES2105108T3 (en) * 1992-04-20 1997-10-16 Sankyo Co STEROIDS FOR THE TREATMENT OF PROSTATIC HYPERTROPHY, ITS PREPARATION AND ITS USE.
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5929058A (en) * 1996-12-24 1999-07-27 Zymogenetics, Inc. Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes
AU8559598A (en) * 1997-08-08 1999-03-01 Ono Pharmaceutical Co. Ltd. Gamma-type regulators for peroxisome proliferator-activated receptor
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
CA2380940C (en) 1999-08-13 2013-06-25 Heinrich Wieland Substances and agents for positively influencing collagen
NL1012886C1 (en) 1999-08-23 2001-02-26 Rephartox 1,4-Dihydropyridine-5-carboxylic acid ester derivatives and process for their preparation.
CO5271688A1 (en) * 1999-11-10 2003-04-30 Pfizer Prod Inc USE OF APOLIPROTEIN B AND / OR SECRETION INHIBITOR OF MICROSMAL TRIGLICERID TRANSFER PROTEIN
DE10054294A1 (en) * 2000-11-02 2002-05-16 Heinrich Wieland Topical treatment for mastalgia
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
MXPA05007572A (en) * 2003-01-17 2005-11-17 Threshold Pharmaceuticals Inc Treatment of benign prostatic hyperplasia.
CA2530047A1 (en) 2003-06-30 2005-02-03 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
JP2007521292A (en) 2003-06-30 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
EP1641535A4 (en) 2003-06-30 2008-05-14 Merck & Co Inc 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2012035553A1 (en) * 2010-09-15 2012-03-22 Ind-Swift Laboratories Limited Process for preparing androstenone derivatives
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
EP2922817A4 (en) * 2012-11-21 2016-06-22 Univ Sydney Omega-3 analogues

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3607651A1 (en) * 1986-03-06 1987-09-10 Schering Ag COMBINATION OF AROMATASE INHIBITORS AND TESTOSTERONE-5 (ALPHA) REDUCTASE INHIBITORS
DK0943328T3 (en) * 1989-07-07 2004-10-18 Endorech Inc Combination therapy for prophylaxis and / or treatment of benign prostatic hyperplasia

Also Published As

Publication number Publication date
AU1893492A (en) 1992-11-17
WO1992018132A1 (en) 1992-10-29
IE921239A1 (en) 1992-10-21
PT100388A (en) 1993-07-30

Similar Documents

Publication Publication Date Title
IL101243A0 (en) Pharmaceutical compositions for treatment of benign prostatic hyperplasia
IL101574A0 (en) Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia
HUP9903732A3 (en) Use of cgmp elevators for the preparation of pharmaceutical compositions treating benign prostatic hyperplasia
EP0667769A4 (en) Use of alpha-1c specific compounds to treat benign prostatic hyperplasia.
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
IL189132A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
EP0626174A3 (en) Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction.
IL143921A0 (en) Compositions for the treatment and prevention of tumors and tumor-related disorders
GB8900678D0 (en) Compositions for the prevention and medical treatment of parodonthopathy
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
HUP9903166A3 (en) Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
IL101245A0 (en) Pharmaceutical compositions for the treatment of prostatic cancer
ZA954984B (en) Compositions and methods for the treatment of tumors
IL101410A0 (en) Formulation for the treatment of cancer
EP0855910A4 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
HUT73678A (en) Compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
NO961226L (en) Compounds for the prevention and treatment of viral-induced tumors
ZA97252B (en) Compositions for the prevention and treatment of osteoporosis.
IL121096A0 (en) Pharmaceutical compositions for the treatment of liver disease
HUP0100781A3 (en) Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia and pharmaceutical compositions containing them
ZA929879B (en) Compositions for the treatment of mammalian diseases.
EP0733365A3 (en) Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer
AU5457694A (en) Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
IL105690A0 (en) Pharmaceutical compositions for the treatment of arrhythmia